KRTAP13-6P

Across TCGA pan-cancer cohorts, KRTAP13-6P RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated KRTAP13-6P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KRTAP13-6P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP13-6P expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LIHC, BLCA, and THCA are the cancer types where KRTAP13-6P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.129	0.707	<.001	108	view →
BLCA	DFS	Tertile	All	0.192	0.619	<.001	99	view →
THCA	OS	Tertile	All	0.575	0.951	<.001	90	view →
STAD	OS	Tertile	IV	1.000	0.271	.014	39	view →
PAAD	OS	Tertile	II,III,IV	0.213	0.556	.014	36	view →
THYM	DFS	Tertile	All	0.075	0.885	<.001	18	view →
MESO	OS	Tertile	All	0.169	0.556	.043	9	view →
SARC	DFS	Tertile	All	0.096	0.591	.006	9	view →
PRAD	OS	Tertile	All	0.932	0.990	.038	6	view →
KIRC	OS	Tertile	All	0.798	0.880	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

KRTAP13-6P–LIHC (OS)

Open the LIHC breakdown →